Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 13,478 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Diabetic Foot Ulcers
Interventions: DSC127, placebo vehicle gel; Drug
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 25
States / cities: Mobile, Alabama • Fair Oaks, California • Fresno, California + 22 more

Conditions: Obesity, Overweight, Type 2 Diabetes Mellitus
Interventions: Maridebart Cafraglutide, Placebo; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 592 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 29
States / cities: Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 20 more

Conditions: Bile Duct Stricture, Cholangiocarcinoma, Pancreatic Cancer, Chronic Pancreatitis
Interventions: brushing of bile duct strictures for cytology; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 99 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Type 2 Diabetes Treated With Insulin
Interventions: t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM); Device
Lead sponsor: Tandem Diabetes Care, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 19
States / cities: Newport Beach, California • Atlanta, Georgia • Idaho Falls, Idaho + 16 more

Conditions: Chromosome 22q11.2 Deletion Syndrome
Interventions: Not listed
Lead sponsor: UMC Utrecht; Other
Eligibility: 8 Years to 20 Years
Enrollment: 175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Choroidal Neovascularization, Diabetic Retinopathy, Diabetic Macular Edema
Interventions: PF-04523655 (Stratum I), ranibizumab, PF-04523655 (Stratum II); Drug
Lead sponsor: Quark Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 20
States / cities: Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 17 more

Conditions: Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions: Carboplatin, Quality-of-Life Assessment, Questionnaire Administration, Cytoreductive Surgery; Drug · Other · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Pancreatic Cancer
Interventions: Simtuzumab, Gemcitabine, Placebo to match simtuzumab; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 44
States / cities: Birmingham, Alabama • Mobile, Alabama • Alhambra, California + 40 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Virtual cooking classes, Routine Diabetes Care; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 12 Years to 17 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes, Diabetes Mellitus
Interventions: Blood draw; Biological
Lead sponsor: MidAtlantic Retina; Other
Eligibility: 18 Minutes and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Gestational Diabetes Mellitus
Interventions: Low Carbohydrate/Conventional, Choosing Healthy Options in Carbohydrate Energy; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Up to 36 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Interventions: Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88; Drug
Lead sponsor: Pancreatic Cancer Action Network; Other
Eligibility: 18 Years and older
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 25
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 18 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID, Placebo; Drug
Lead sponsor: vTv Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 47
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Concord, California + 41 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 56
States / cities: Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 47 more

Conditions: Diabetes Mellitus, Type 2
Interventions: dulaglutide, Warfarin; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pancreatic Cancer
Interventions: ABTL0812, Folfirinox, Placebo; Drug
Lead sponsor: Ability Pharmaceuticals SL; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Los Angeles, California • Westwood, Kansas • Boston, Massachusetts + 1 more

Conditions: Brenner Tumor, Fallopian Tube Cancer, Ovarian Carcinosarcoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Primary Peritoneal Cavity Cancer, Stage II Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions: carboplatin, paclitaxel, docetaxel, bevacizumab; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 16
States / cities: Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more

Conditions: Pancreatic Cancer, Biliary Cancer
Interventions: gemcitabine, capecitabine; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: San Francisco, California • Salt Lake City, Utah

Conditions: Type 2 Diabetes
Interventions: herbal extract; root of woody shrub grown in India/Sri-Lanka; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Edina, Minnesota • Cincinnati, Ohio

Conditions: Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Carcinosarcoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Carcinosarcoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine, Pembrolizumab, Pheresis; Procedure · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Metabolic Syndrome X, Diabetes Mellitus, Type 2
Interventions: topiramate; Drug
Lead sponsor: Northeastern Ohio Universities College of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 5
States / cities: Akron, Ohio • Canton, Ohio • Youngstown, Ohio

Conditions: Diabetic Retinopathy, Diabetic Macular Edema, DME
Interventions: Triamcinolone Acetonide; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer, Colorectal Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Acral Lentiginous Melanoma, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, Esophageal Squamous Cell Carcinoma, Urothelial Carcinoma, DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Melanoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer
Interventions: ATRC-101, Pembrolizumab, Pegylated liposomal doxorubicin (PLD); Biological · Drug
Lead sponsor: Atreca, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 19
States / cities: Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more

Conditions: Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndromes, Neoplasms, Melanoma, Breast Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Renal Cell Carcinoma, Glioblastoma Multiforme, Osteosarcoma, Sarcoma, Thyroid Cancer, Genitourinary
Interventions: CC-486, Vidaza; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 10
States / cities: Scottsdale, Arizona • Tucson, Arizona • Iowa City, Iowa + 6 more

Search by objective public record fields.

Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers

Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

Diagnosis of Bile Duct Strictures

A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

Genetics and Psychopathology in the 22q11 Deletion Syndrome

PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)

Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Phipps Conservatory's 5210 Let's Move Pittsburgh and Impact on Youth With T1D

Thrombospondin-1 and Pigmented Epithelium Derived Factor Levels in Patients With Diabetes Mellitus.

Trial of Diet in Gestational Diabetes Mellitus: Metabolic Consequences to Mother and Offspring

A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants

ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)

Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers

Efficacy Study Testing Herbal Extract on Metabolic Parameters in Subjects With Type 2 Diabetes

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Efficacy of Topiramate for Weight Loss in Subjects With Metabolic Syndrome

Treatment of Diabetic Macular Edema: Triamcinolone Injections Vs. Laser Photocoagulation

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies